Published in Lancet on January 01, 1983
Scandinavian model for eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) (1984) 3.25
Immunisation policies. Br Med J (Clin Res Ed) (1983) 1.46
Measles and rubella: our remaining responsibilities. Am J Public Health (1983) 1.23
Immunisation policies. Br Med J (Clin Res Ed) (1983) 1.20
Rubella in Europe. Epidemiol Infect (1991) 1.18
Rubella vaccination: a course becomes clear. Can Med Assoc J (1983) 1.10
Strategies to eradicate rubella in the English-speaking Caribbean. Am J Public Health (2000) 1.05
Rubella immunisation: whose baby? Br Med J (Clin Res Ed) (1984) 0.94
Rubella in the developing world. Epidemiol Infect (1991) 0.88
Preventing the congenital rubella syndrome by vaccinating women at risk. Can Med Assoc J (1983) 0.77
Maternal and fetal well-being. West J Med (1984) 0.77
Role of the occupational health service in increasing the uptake of rubella immunisation. Br Med J (Clin Res Ed) (1985) 0.75
Characterization of rubella seronegative females in the zambian blood donor community. Front Public Health (2015) 0.75
Immunisation practice and policy. J Epidemiol Community Health (1984) 0.75
Immunisation policies. Br Med J (Clin Res Ed) (1983) 0.75
Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med (2000) 6.43
Field evaluation of vaccine efficacy. Bull World Health Organ (1985) 4.95
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med (2000) 3.65
Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev (1988) 3.51
Immunization policies and vaccine coverage among adults. The risk for missed opportunities. Ann Intern Med (1988) 3.49
AIDS and absolutism--the demand for perfection in prevention. N Engl J Med (1992) 3.03
Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics (1978) 2.98
The opportunity and obligation to eliminate measles from the United States. JAMA (1979) 2.93
Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health (1985) 2.58
The immunization system in the United States - the role of school immunization laws. Vaccine (1999) 2.57
Tuberculosis symposium: emerging problems and promise. J Infect Dis (1993) 2.55
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med (1989) 2.41
The sample household health interview survey. Am J Public Health (1982) 2.35
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol (1987) 2.13
Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol (1989) 2.12
Developing the Guide to Community Preventive Services--overview and rationale. The Task Force on Community Preventive Services. Am J Prev Med (2000) 2.10
Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol (1985) 2.09
Improving immunization coverage rates: an evidence-based review of the literature. Epidemiol Rev (1999) 2.09
Use of health services. Am J Public Health (1982) 2.06
Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol (1986) 1.93
From the Center for Disease control: current status of measles in the United States, 1973--1977. J Infect Dis (1978) 1.91
Progress in measles elimination. JAMA (1982) 1.87
Appropriate age for measles vaccination in the United States. Dev Biol Stand (1986) 1.80
Low measles incidence: association with enforcement of school immunization laws. Am J Public Health (1981) 1.79
Age-specific risks of varicella complications. Pediatrics (1981) 1.76
Current features of measles in the United States: feasibility of measles elimination. Epidemiol Rev (1980) 1.76
Costs of care. Am J Public Health (1982) 1.74
Costs of immunization registries: experiences from the All Kids Count II Projects. Am J Prev Med (2000) 1.72
The resurgence of measles in the United States, 1989-1990. Annu Rev Med (1992) 1.72
The case for global eradication of poliomyelitis. Bull World Health Organ (1987) 1.72
Health impact of measles vaccination in the United States. Pediatrics (1985) 1.71
Current status of mumps and mumps vaccine in the United States. Pediatrics (1978) 1.71
Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health (1987) 1.70
Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 1.70
Outbreak of paralytic poliomyelitis, Taiwan. Lancet (1984) 1.68
Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet (1990) 1.67
Health services in Shanghai County: introduction to Shanghai County. Am J Public Health (1982) 1.63
Epidemiology of pertussis, Atlanta, 1977. J Pediatr (1981) 1.62
Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA (1984) 1.59
Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics (1989) 1.57
Rubella vaccination in the United States: a ten-year review. Epidemiol Rev (1980) 1.53
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am J Epidemiol (1989) 1.53
Elimination of indigenous measles from the United States. Rev Infect Dis (1983) 1.50
Fetal risk associated with rubella vaccine: an update. Rev Infect Dis (1985) 1.50
Causes of low preschool immunization coverage in the United States. Annu Rev Public Health (1992) 1.45
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. Am J Epidemiol (1995) 1.43
Resurgence of measles in New York. Am J Public Health (1972) 1.43
Global progress in infectious disease control. Vaccine (1998) 1.42
The Russian flu. Its history and implications for this year's influenza season. JAMA (1978) 1.41
Varicella: complications and costs. Pediatrics (1986) 1.41
A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep (1992) 1.41
Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis (1970) 1.40
Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis (1985) 1.39
DTP vaccine litigation, 1988. Am J Dis Child (1990) 1.39
Measles surveillance--United States, 1991. MMWR CDC Surveill Summ (1992) 1.38
An epidemiological assessment of cholera control programs in rural East Pakistan. Int J Epidemiol (1972) 1.36
Increasing the supply of cadaveric kidneys for transplantation. Transplantation (1981) 1.35
Pertussis--a disease and a vaccine that are not going away. West J Med (1989) 1.35
Major impediments to measles elimination. The modern epidemiology of an ancient disease. Am J Dis Child (1985) 1.32
Increased lead absorption with anemia and slowed nerve conduction in children near a lead smelter. J Pediatr (1976) 1.32
Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics (1978) 1.30
Structuring HIV prevention service delivery systems on the basis of social science theory. J Community Health (1992) 1.29